August 20,
2014: Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark
Pharmaceuticals Limited India (GPL), announces
the discovery and initiation of IND enabling
studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 was discovered and developed by
the Glenmark Biologics Research
Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark’s innovative
BEAT antibody technology platform which facilitates the efficient development
and manufacture of antibodies with dual specificities, so-called bispecific
antibodies. GBR 1302 is the first clinical development candidate based on the
BEAT technology. Glenmark expects to obtain approval for the initiation of
clinical studies during this financial year.·GBR 1302 is the first bispecific antibody based on Glenmark’s proprietary BEAT platform
·
GBR 1302 is Glenmark’s first clinical candidate
targeting oncology indications
Glenmark Pharmaceuticals announced the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody technology platform which facilitates the efficiend development and manufacture of antibodies with dual specificities, so-called bispecific antibodies. GBR 1302 is the first clinical development candidate based on the BEAT technology.Glenmark expect to obtain approval for the initiation of clinical studies during this financial year.
read at
http://www.sharekhan.com/stock-market/news/Glenmark-enters-Oncology-with-the-Discov/879A76C4-601D-40F7-B402-BCD9BACED8E3/MustKnowNews/161/News.htmGlenmark Pharmaceuticals announced the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody technology platform which facilitates the efficiend development and manufacture of antibodies with dual specificities, so-called bispecific antibodies. GBR 1302 is the first clinical development candidate based on the BEAT technology.Glenmark expect to obtain approval for the initiation of clinical studies during this financial year.
read at
